Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 355-362

  Schuster, Herbert ^a   Fagerberg, Björn ^b   Edwards, Siôn ^c   Halmos, Tamas ^d   Lopatynski, Jerzy ^e   Stender, Steen ^f   Birketvedt, Grethe Stoa ^g   Tonstad, Serena ^h   Gause Nilsson, Ingrid ⁱ   Halldórsdóttir, Sigrún ⁱ   Öhman, K Peter ^j  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c North Cardiff Medical Centre   (United Kingdom)

^d NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^e Lublin Medical Academy   (Poland)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g AKER UNIVERSITY HOSPITAL   (Norway)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ ASTRAZENECA R AND D   (Sweden)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

Apolipoprotein; Atherosclerosis; Dyslipidaemia; Hypertriglyceridaemia; Insulin resistance; Peroxisome proliferator activated receptor

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHOLESTEROL; FAS ANTIGEN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; TESAGLITAZAR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 39449103963     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.05.029     Document Type: Article

References (32)

1. Sniderman A.D., Scantlebury T., and Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135 (2001) 447-459
2. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 94 (1996) 273-278
3. Lee S.J., Campos H., Moye L.A., and Sacks F.M. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 23 (2003) 853-858
4. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol And Recurrent Events (CARE) trial. Circulation 102 (2000) 1886-1892
5. Wagner A.M., Perez A., Calvo F., et al. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care 22 (1999) 812-817
6. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
7. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
8. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 99 (1999) 2517-2522
9. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113 (2006) 20-29
10. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2006;June 9 [Epub ahead of print].
11. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
12. Fruchart J.C., Duriez P., and Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10 (1999) 245-257
13. Duez H., Lefebvre B., Poulain P., et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 25 (2005) 585-591
14. Kendall D.M., Rubin C.J., Mohideen P., et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29 (2006) 1016-1023
15. Packard C.J., Demant T., Stewart J.P., et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41 (2000) 305-318
16. Fagerberg B., Edwards S., Halmos T., et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (2005) 1716-1725
17. Goldstein B., Rosenstock J., Anzalone D., Tou C., and Ohman K.P. Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin 22 12 (2006) 2575-2590
18. Karter A.J., Mayer-Davis E.J., Selby J.V., et al. Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 45 (1996) 1547-1555
19. Katsuki A., Sumida Y., Urakawa H., et al. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 26 (2003) 2341-2344
20. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7-18
21. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46 (1997) 3-10
22. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
23. Linden D., Lindberg K., Oscarsson J., et al. Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. J Biol Chem 277 (2002) 23044-23053
24. Koh K.K., Han S.H., Quon M.J., Yeal A.J., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
25. Mussoni L., Mannucci L., Sirtori C., et al. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis 148 (2000) 397-406
26. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106 (2000) 467-472
27. Fredenrich A. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism. Diabetes Metab 24 (1998) 490-495
28. Tomiyasu K., Walsh B.W., Ikewaki K., Judge H., and Sacks F.M. Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol 21 (2001) 1494-1500
29. Gervaise N., Garrigue M.A., Lasfargues G., and Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 43 (2000) 703-708
30. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
31. Chinetti G., Lestavel S., Fruchart J.C., Clavey V., and Staels B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res 92 (2003) 212-217
32. Miremadi S., Sniderman A., and Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?. Clin Chem 48 (2002) 484-488